Copyright © 2026 AudiologyOnline - All Rights Reserved

AudiologyOnline Phone: 800-753-2160

Exam Preview

How to Start a cCMV Screening Program, in partnership with the American Academy of Audiology

View Course Details Please note: exam questions are subject to change.
Print

1.  Congenital cytomegalovirus (cCMV) is best described as which of the following?
  1. A rare genetic disorder affecting hearing only
  2. A common DNA virus that is usually harmless but can cause congenital infection
  3. A bacterial infection transmitted only during delivery
  4. A vaccine-preventable childhood illness
2.  Which of the following is the most common non-hereditary cause of congenital sensorineural hearing loss?
  1. Ototoxic medication exposure
  2. Prematurity
  3. Congenital cytomegalovirus
  4. Noise exposure
3.  Which of the following is true of infants with “asymptomatic” congenital CMV?
  1. They always develop hearing loss
  2. They may have a normal physical exam but still develop hearing loss
  3. They always show brain abnormalities on imaging
  4. They only develop conductive hearing loss
4.  Why is cCMV screening time-sensitive?
  1. Treatment is only effective in the first 7 days
  2. Maternal antibodies disappear after birth
  3. Samples must be collected before 21 days of age to confirm congenital infection
  4. Hearing loss always presents within the first week of life
5.  Which group is typically included in hearing-targeted cCMV screening programs?
  1. All newborns regardless of hearing status
  2. Infants who fail the newborn hearing screen
  3. Infants born prematurely
  4. Infants admitted to the NICU only
6.  Which screening approach detects all infants with congenital CMV?
  1. Hearing-targeted screening
  2. Expanded targeted screening
  3. Universal cCMV screening
  4. NICU-only screening
7.  What percentage of infants with cCMV who later develop hearing loss may pass the newborn hearing screen?
  1. 5%
  2. 15%
  3. 25%
  4. 43%
8.  Which specimen is considered an appropriate test for diagnosing congenital CMV within the first 21 days of life?
  1. CMV IgG antibody testing
  2. Serum collected after 3 weeks of age
  3. Saliva PCR
  4. Hearing screening results alone
9.  What is a major limitation of dried blood spot (DBS) testing for cCMV?
  1. It cannot be used after birth
  2. It has low sensitivity and delayed turnaround time
  3. It is more expensive than saliva testing
  4. It is not accepted by public health programs
10.  Which of the following is a key component of a successful cCMV screening program?
  1. Screening without a follow-up plan
  2. Limiting communication to audiology only
  3. A written protocol with defined roles and follow-up procedures
  4. Testing only after hearing loss is confirmed